Humacyte, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 110.78 million compared to USD 11.97 million a year ago. Basic loss per share from continuing operations was USD 1.07 compared to USD 0.12 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.42 USD | +17.15% | +39.26% | +126.06% |
05-10 | Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024 | |
03-28 | Transcript : Humacyte, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+126.06% | 653M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- HUMA Stock
- News Humacyte, Inc.
- Humacyte, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023